| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.6K | 7.0% | 14.0% |
| Total Income | 1.6K | 7.0% | 14.0% |
| Expenditure | 2.3K | 132.1% | 145.6% |
| PBT | -688.85 | 191.7% | 242.8% |
| Net Profit | -784.80 | 234.0% | 285.0% |
| OPM | -45.49% | 87.18pp | 77.96pp |
| NPM | -50.40% | 85.38pp | 81.45pp |
| EPS | -3.86 | 232.2% | 277.9% |
Incyte Reports Q3 2026 Financial Results and Provides Business Updates
29 Oct 2026 · 1d ago, 4:37 pm
Summary
Incyte Corporation reported strong third quarter 2026 financial results, with total revenue reaching $1.56 billion, a 14% increase year-over-year, and total net sales also growing 14% to $1.32 billion. Key drivers included significant growth in Opzelura net sales (up 36%) and the Hematology and Oncology portfolio (up 38%), alongside a 4% increase in Jakafi net sales. The company is raising its full-year 2026 guidance for Opzelura, Hematology and Oncology net sales, and total net sales, reflecting continued strong performance across its marketed products. Management highlighted meaningful pipeline progress and important regulatory achievements, with several late-stage development programs advancing.
Key Highlights
- 1
Total revenue increased by 14% to $1.56 billion in the third quarter of 2026 compared to the third quarter of 2025.
- 2
Total net sales grew by 14% year-over-year to $1.32 billion in Q3 2026.
- 3
Jakafi net sales increased by 4% to $827 million in the third quarter of 2026 compared to the prior year period.
- 4
Opzelura net sales saw a significant increase of 36% to $255 million in Q3 2026 versus the prior year period.
- 5
Hematology and Oncology portfolio net sales rose by 38% to $235 million in the third quarter of 2026 compared to Q3 2025.
- 6
Incyte is raising its full year 2026 financial guidance for Opzelura net sales, Hematology and Oncology net sales, and total net sales.
- 7
Phase 1 data for INCB161734 and INCA033890 support an expanding GI Oncology development strategy with multiple registrational studies planned for 2027.
Management Comments
Bill Meury
Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements. Net sales growth was strong in both the U.S. and internationally, creating a durable core business beyond Jakafi. At the same time, we are advancing a pipeline led by a CALR-targeted monoclonal antibody for myeloproliferative neoplasms, a novel Protein S modulator for von Willebrand disease, a KRAS G12D inhibitor for pancreatic and colorectal cancers and a TGFβR2×PD-1 bispecific antibody for colorectal cancer. Each represents a significant opportunity for Incyte, and together they give us multiple paths to growth beyond 2029. With important clinical, regulatory and commercial catalysts ahead, we are well positioned to create long-term value for patients and shareholders.
Informational and educational content only. Not investment advice.